Autres langues Basilea Pharmaceutica AG

Actions

BSLN

CH0011432447

Recherche biotechnologique et médicale

Marché Fermé - Swiss Exchange 17:31:44 31/08/2026			Varia. 5j.	Varia. 1 janv.
63,50 ^CHF	-1,55%		-1,85%	+16,09%

18/08	Basilea Pharmaceutica AG relève ses prévisions de résultats pour l'exercice 2026	CI
18/08	Le Swiss Market Index clôture en hausse ; l'action Huber+Suhner chute	MT

Autres langues

18/08	Basilea Pharmaceutica Ag Raises Earnings Guidance for the Full Year 2026
18/08	Swiss Market Index Closes Higher; Huber+Suhner Shares Drop
18/08	Aktien Schweiz gut behauptet - Defensive Index-Schwergewichte stützen
18/08	Aktien Schweiz: Nahostsorgen und höhere Zinsen bremsen den SMI
18/08	Basilea-Aktien nach Zahlen und erhöhtem Ausblick gesucht
18/08	Basilea Pharmaceutica AG Reports Earnings Results for the Half Year Ended June 30, 2026
18/08	Basilea schraubt nach erstem Semester Ziele hoch
18/08	Basilea Pharmaceutica Posts Higher H1 Net Profit, Total Revenue
18/08	Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
18/08	Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
18/08	Basilea erzielt starkes Halbjahresergebnis 2026 und erhöht die Finanzprognose für das Gesamtjahr; Phase-3-Programm mit Fosmanogepix auf Kurs
18/08	Swiss stocks - Factors to watch on August 18
05/08	Swiss Market Index Extends Rally; Sandoz Shares Gain
05/08	Basilea erhält weitere 5,4 Mio USD von BARDA für Antibiotika-Entwicklung
05/08	Basilea Pharmaceutica Bags Additional $5 Million Funding for Antibiotic Development
05/08	Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
05/08	Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
05/08	Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam
05/08	Basilea Pharmaceutica Ltd Receives Additional Funding to Continue Development of Novel Antibiotic Ceftibuten-Ledaborbactam Etzadroxil
05/08	Basilea Pharmaceutica Ltd Receives Additional USD 5.4 Million Funding From Biomedical Advanced Research And Development Authority To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam Etzadroxil
29/07	Basilea Receives USD 30 Million Funding Under Existing BARDA Agreement for Advancing Phase 3 Development of Novel Antifungal Fosmanogepix
29/07	Basilea erhält weitere 30 Mio Dollar für Fosmanogepix-Studie von BARDA
29/07	Basilea Pharmaceutica Bags Additional $30 Million Funding for Antifungal Development
29/07	Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
29/07	Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix